HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients

Despite the outstanding progresses in Multiple Myeloma treatment options in the last decades, it remains an incurable disease nowadays. Infectious events are a complication due to an impaired immune system associated with MM, sometimes a life-threatening one, particularly on the first months after t...

Full description

Bibliographic Details
Main Authors: Jose Luis Garcia de Veas Silva, Maria Trinidad Gonzalez Cejudo, Alberto Garcia Perojil Jimenez, Maria del Señor Garcia Lopez Velez, Rafael Garcia Rios Tamayo, Carmen Garcia Bermudo Guitarte, Tomas Garcia De Haro Muñoz
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.599532/full
_version_ 1819141415993606144
author Jose Luis Garcia de Veas Silva
Maria Trinidad Gonzalez Cejudo
Alberto Garcia Perojil Jimenez
Maria del Señor Garcia Lopez Velez
Rafael Garcia Rios Tamayo
Carmen Garcia Bermudo Guitarte
Tomas Garcia De Haro Muñoz
author_facet Jose Luis Garcia de Veas Silva
Maria Trinidad Gonzalez Cejudo
Alberto Garcia Perojil Jimenez
Maria del Señor Garcia Lopez Velez
Rafael Garcia Rios Tamayo
Carmen Garcia Bermudo Guitarte
Tomas Garcia De Haro Muñoz
author_sort Jose Luis Garcia de Veas Silva
collection DOAJ
description Despite the outstanding progresses in Multiple Myeloma treatment options in the last decades, it remains an incurable disease nowadays. Infectious events are a complication due to an impaired immune system associated with MM, sometimes a life-threatening one, particularly on the first months after the diagnosis. Both the underlying disease and treatment can contribute to the infection risk, so a biomarker that assess this risk could be highly relevant for a more tailored management of the patient. The measurement of the heavy+light chain (HLC) pairs of immunoglobulins in serum allows the quantification of both the monoclonal component and the non-monoclonal immunoglobulin of the same isotype. This approach has demonstrated high sensitivity for the detection of the clonality and prognostic value for MM. HLC pair suppression itself has prognostic power and it has been proposed to be a reflection of the immune system’ attempt to control the tumor. In this study we evaluated the impact of the HLC pair suppression on the rate of bloodstream infections (BSI) and early death in 115 newly diagnosed MM patients. Twenty-one percent of the patients suffered a BSI in the first 6 months after diagnosis, of which 58% died within this period, accounting to 67% of the early deaths in global and highlighting the major impact of infections on MM patients in a “real world” setting. Severe HLC pair suppression identified patients with a higher risk of early BSI (HR: 6,97, p=0,009), and extreme HLC pair suppression together with BSI event and age >65 were independent risk factors for early death (p<0,001). Based on these factors, a stratification model was generated to allow identify patients at a higher risk of early death and poorer OS, with an apparently better performance than the ISS on the early death context. In conclusion, HLC pair suppression associates with both a higher risk of life-threatening early infection and early death in newly diagnosed MM patients. Patients older than 65 with extreme HLC pair suppression and BSI are at a high risk of early death, and thus patients presenting with these criteria have a very adverse prognosis.
first_indexed 2024-12-22T11:54:06Z
format Article
id doaj.art-2b2d13b1588a49eba7b90cdf965fdca9
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-22T11:54:06Z
publishDate 2021-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-2b2d13b1588a49eba7b90cdf965fdca92022-12-21T18:26:53ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-03-011110.3389/fonc.2021.599532599532HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma PatientsJose Luis Garcia de Veas Silva0Maria Trinidad Gonzalez Cejudo1Alberto Garcia Perojil Jimenez2Maria del Señor Garcia Lopez Velez3Rafael Garcia Rios Tamayo4Carmen Garcia Bermudo Guitarte5Tomas Garcia De Haro Muñoz6Department of Laboratory Medicine, Hospital Universitario San Cecilio, Granada, SpainDepartment of Laboratory Medicine, Hospital Universitario San Cecilio, Granada, SpainDepartment of Laboratory Medicine, Hospital Universitario San Cecilio, Granada, SpainDepartment of Laboratory Medicine, Hospital Universitario San Cecilio, Granada, SpainDepartment of Hematology, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartment of Clinical Biochemistry, Hospital Universitario Virgen Macarena, Seville, SpainDepartment of Laboratory Medicine, Hospital Universitario San Cecilio, Granada, SpainDespite the outstanding progresses in Multiple Myeloma treatment options in the last decades, it remains an incurable disease nowadays. Infectious events are a complication due to an impaired immune system associated with MM, sometimes a life-threatening one, particularly on the first months after the diagnosis. Both the underlying disease and treatment can contribute to the infection risk, so a biomarker that assess this risk could be highly relevant for a more tailored management of the patient. The measurement of the heavy+light chain (HLC) pairs of immunoglobulins in serum allows the quantification of both the monoclonal component and the non-monoclonal immunoglobulin of the same isotype. This approach has demonstrated high sensitivity for the detection of the clonality and prognostic value for MM. HLC pair suppression itself has prognostic power and it has been proposed to be a reflection of the immune system’ attempt to control the tumor. In this study we evaluated the impact of the HLC pair suppression on the rate of bloodstream infections (BSI) and early death in 115 newly diagnosed MM patients. Twenty-one percent of the patients suffered a BSI in the first 6 months after diagnosis, of which 58% died within this period, accounting to 67% of the early deaths in global and highlighting the major impact of infections on MM patients in a “real world” setting. Severe HLC pair suppression identified patients with a higher risk of early BSI (HR: 6,97, p=0,009), and extreme HLC pair suppression together with BSI event and age >65 were independent risk factors for early death (p<0,001). Based on these factors, a stratification model was generated to allow identify patients at a higher risk of early death and poorer OS, with an apparently better performance than the ISS on the early death context. In conclusion, HLC pair suppression associates with both a higher risk of life-threatening early infection and early death in newly diagnosed MM patients. Patients older than 65 with extreme HLC pair suppression and BSI are at a high risk of early death, and thus patients presenting with these criteria have a very adverse prognosis.https://www.frontiersin.org/articles/10.3389/fonc.2021.599532/fullmyelomaprognostic factorHLC (heavy/light chain)infectionimmunoparesis
spellingShingle Jose Luis Garcia de Veas Silva
Maria Trinidad Gonzalez Cejudo
Alberto Garcia Perojil Jimenez
Maria del Señor Garcia Lopez Velez
Rafael Garcia Rios Tamayo
Carmen Garcia Bermudo Guitarte
Tomas Garcia De Haro Muñoz
HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients
Frontiers in Oncology
myeloma
prognostic factor
HLC (heavy/light chain)
infection
immunoparesis
title HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients
title_full HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients
title_fullStr HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients
title_full_unstemmed HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients
title_short HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients
title_sort hlc pair suppression as a risk factor for bacterial bloodstream infections and early mortality in newly diagnosed intact immunoglobulin multiple myeloma patients
topic myeloma
prognostic factor
HLC (heavy/light chain)
infection
immunoparesis
url https://www.frontiersin.org/articles/10.3389/fonc.2021.599532/full
work_keys_str_mv AT joseluisgarciadeveassilva hlcpairsuppressionasariskfactorforbacterialbloodstreaminfectionsandearlymortalityinnewlydiagnosedintactimmunoglobulinmultiplemyelomapatients
AT mariatrinidadgonzalezcejudo hlcpairsuppressionasariskfactorforbacterialbloodstreaminfectionsandearlymortalityinnewlydiagnosedintactimmunoglobulinmultiplemyelomapatients
AT albertogarciaperojiljimenez hlcpairsuppressionasariskfactorforbacterialbloodstreaminfectionsandearlymortalityinnewlydiagnosedintactimmunoglobulinmultiplemyelomapatients
AT mariadelsenorgarcialopezvelez hlcpairsuppressionasariskfactorforbacterialbloodstreaminfectionsandearlymortalityinnewlydiagnosedintactimmunoglobulinmultiplemyelomapatients
AT rafaelgarciariostamayo hlcpairsuppressionasariskfactorforbacterialbloodstreaminfectionsandearlymortalityinnewlydiagnosedintactimmunoglobulinmultiplemyelomapatients
AT carmengarciabermudoguitarte hlcpairsuppressionasariskfactorforbacterialbloodstreaminfectionsandearlymortalityinnewlydiagnosedintactimmunoglobulinmultiplemyelomapatients
AT tomasgarciadeharomunoz hlcpairsuppressionasariskfactorforbacterialbloodstreaminfectionsandearlymortalityinnewlydiagnosedintactimmunoglobulinmultiplemyelomapatients